Wish to keep on prime of the science and politics driving biotech in the present day? Join to get our biotech publication in your inbox.
Hiya, everybody. Damian right here with a have a look at key Supreme Court docket choice, the most recent biotech IPO, and intrigue over Chinese language outsourcing.
Is pharma caught in a commerce struggle?
Who will get to sue the FDA? And what does “AF” stand for?
We cowl all that and extra this week on “The Readout LOUD,” STAT’s biotech podcast. Our colleague Sarah Owermohle joins us to elucidate the Supreme Court docket case that would have dramatic results on entry to treatment abortion — and the event of recent medicines. We additionally focus on the most recent information within the life sciences, together with a contrarian tackle a brand new weight problems therapy and the way we managed to make 300 episodes of this podcast.
Hear right here.
Excellent news and unhealthy information for biotech IPOs
Boundless Bio, a cancer-focused agency, raised $100 million in one among 2024’s few biotech IPOs yesterday. After which its share worth fell about 9% on a day biotech shares have been flat.
Regardless of the fast decline, Boundless now has the money to push ahead with a pipeline of therapies aimed on the rings of DNA present in tumors however absent from wholesome cells. Roughly 15% of cancers have that so-called extrachromosomal DNA, and Boundless is growing therapies to dam the organic course of that produces it. The corporate’s lead drug is in Section 1, with information anticipated within the second half of this yr.
As for biotech at giant, Boundless turns into simply the ninth firm to efficiently go public in 2024. That’s a mere fraction of the greater than 70 IPOs recorded throughout the sector’s 2021 boom, but it surely places the trade on tempo to double 2023’s numbers, suggesting biotech would possibly lastly be heading for some equanimity.
What’s Congress going to do with WuXi?
For weeks, members of Congress have debated laws that may successfully ban a handful of Chinese language life sciences firms from doing enterprise within the U.S., pushed by considerations that they may misuse genomic information. Curiously listed amongst them was WuXi AppTec, a agency that conducts outsourced analysis and manufacturing for drug firms and appeared far faraway from the spirit of the laws.
However the story seems to be extra sophisticated. Reuters reported yesterday that U.S. intelligence officers consider WuXi handed an American consumer’s mental property on to Chinese language authorities with out permission, citing two folks acquainted with the matter. WuXi mentioned it complies with U.S. legal guidelines and has no information of such an incident. Nobody else concerned is commenting.
WuXi, which will get about 65% of its income from U.S. purchasers, has “been actively working … to set the file straight and advocate for adjustments to the proposed laws,” the corporate mentioned earlier this month.
Extra reads
- A contrarian view on Viking Therapeutics, biotech’s hottest weight problems inventory, STAT
- Bernie Sanders needs to satisfy Novo CEO subsequent week on Ozempic worth, Bloomberg
- U.Ok. turns into the primary nation to launch detailed information on sponsors that fail to register scientific trials, STAT
- Blackstone cures two illnesses in a single Moderna shot, Reuters
